...
首页> 外文期刊>JMIR cardio. >A Novel Intelligent Two-Way Communication System for Remote Heart Failure Medication Uptitration (the CardioCoach Study): Randomized Controlled Feasibility Trial
【24h】

A Novel Intelligent Two-Way Communication System for Remote Heart Failure Medication Uptitration (the CardioCoach Study): Randomized Controlled Feasibility Trial

机译:用于远程心力衰竭药物治疗的新型智能双向通信系统(CardioCoach研究):随机对照可行性试验

获取原文
           

摘要

Background: European Society of Cardiology guidelines for the treatment of heart failure (HF) prescribe uptitration of angiotensin-converting enzyme inhibitors (ACE-I) and β-blockers to the maximum-tolerated, evidence-based dose. Although HF prognosis can drastically improve when correctly implementing these guidelines, studies have shown that they are insufficiently implemented in clinical practice. Objective: The aim of this study was to verify whether supplementing the usual care with the CardioCoach follow-up tool is feasible and safe, and whether the tool is more efficient in implementing the guideline recommendations for β-blocker and ACE-I. Methods: A total of 25 HF patients were randomly assigned to either the usual care control group (n=10) or CardioCoach intervention group (n=15), and observed for 6 months. The CardioCoach follow-up tool is a two-way communication platform with decision support algorithms for semiautomatic remote medication uptitration. Remote monitoring sensors automatically transmit patient’s blood pressure, heart rate, and weight on a daily basis. Results: Patients’ satisfaction and adherence for medication intake (10,018/10,825, 92.55%) and vital sign measurements (4504/4758, 94.66%) were excellent. However, the number of technical issues that arose was large, with 831 phone contacts (median 41, IQR 32-65) in total. The semiautomatic remote uptitration was safe, as there were no adverse events and no false positive uptitration proposals. Although no significant differences were found between both groups, a higher number of patients were on guideline-recommended medication dose in both groups compared with previous reports. Conclusions: The CardioCoach follow-up tool for remote uptitration is feasible and safe and was found to be efficient in facilitating information exchange between care providers, with high patient satisfaction and adherence.
机译:背景:欧洲心脏病学会心力衰竭(HF)治疗指南规定将血管紧张素转换酶抑制剂(ACE-I)和β受体阻滞剂调高至最大耐受,循证剂量。尽管正确实施这些指导原则可大大改善HF的预后,但研究表明,在临床实践中未充分实施这些指导。目的:这项研究的目的是验证用CardioCoach随访工具补充常规护理是否可行和安全,以及该工具在实施针对β受体阻滞剂和ACE-I的指南建议中是否更有效。方法:总共25例HF患者被随机分为常规护理对照组(n = 10)或CardioCoach干预组(n = 15),并观察6个月。 CardioCoach跟踪工具是一个双向通信平台,具有用于半自动远程药物调配的决策支持算法。远程监控传感器每天自动传输患者的血压,心率和体重。结果:患者对药物摄入的满意度和依从性(10,018 / 10,825,92.55%)和生命体征测量(4504/4758,94.66%)极好。但是,出现的技术问题数量很大,总共有831个电话联系(中位数41,IQR 32-65)。半自动远程调整是安全的,因为没有不良事件,也没有虚假的积极调整建议。尽管两组之间均未发现明显差异,但与先前的报告相比,两组中接受指南推荐药物剂量的患者均较多。结论:用于远程翻身的CardioCoach后续工具既可行又安全,并且被发现可以有效地促进护理人员之间的信息交换,并具有很高的患者满意度和依从性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号